Scott Aaronson, MD, is director of clinical research programs, director of transcranial magnetic stimulation services, and chair of the medical executive committee at Sheppard Pratt Health System in Baltimore, Maryland. He is an Adjunct Professor in the Department of Psychiatry at the University of Maryland School of Medicine. Dr Aaronson specializes in treatment-resistant affective disorders. He is a thought leader in the areas of biological psychiatry, diagnosis, and the integration of somatic and psychological therapies, and is principal investigator for multiple studies on the development of novel therapies for mood and anxiety disorders. Dr Aaronson is a valued speaker and educator and frequently lectures both regionally and nationally on mood disorders, including integration of biological and psychotherapies, complex mood disorders, psychoeducation, and the development of new therapies. Much of his research work and publications center on the development of various neurostimulation paradigms including Transcranial Magnetic Stimulation, Vagus Nerve Stimulation, Direct Current Stimulation and synchronized TMS to treat severe mood disorders. Recently, he has begun research into the use of psychedelics in mood disorders including three studies looking at psilocybin in various presentations of depression. He is a member of the board of directors of the Clinical TMS Society and the American Society for Clinical Psychopharmacology. Dr Aaronson earned his MD with honors from Harvard Medical School. He completed a residency in psychiatry at McLean Hospital, as well as a fellowship in sleep physiology at Harvard Medical School. He is a Distinguished Life Fellow of the American Psychiatric Association and a Fellow of the American College of Psychiatrists.
To contact GME, email us at [email protected]